Jin Shin Jyutsu Helps Cancer Patients Deal With Symptoms

According to a paper presented at the 2012 Markey Cancer Center Research Day, the stress, the pain and the nausea experienced by cancer patients can be relieved after just one session of touch therapy. The study further showed that progressive sessions demonstrate a continued decrease in these unfortunate cancer side effects.

The study was presented by Jennifer Bradley, a Jin Shin Jyutsu integrative practitioner who works out of the University of Kentucky Markey Cancer Center.

Her study included 159 patients at the University of Kentucky Markey Cancer Center and used a self-reported scale of 0 to 10 regarding their experiences with those three symptoms: pain, nausea and stress. Patients reported their experiences before and after the Jin Shin Jyutsu sessions.

Bradley and her team determined that Jin Shin Jyutsu session was effective in reducing the patients' stress, pain and nausea from the very first session, with the average decrease on the scale being three points for stress and two points for nausea as well as pain.

The University of Kentucky Markey Cancer Center offers Jin Shin Jyutsu free to its cancer patients and is part of the hospital's integrative treatment plan.

Jin Shin Jyutsu consists of touch therapy at 52 predetermined, specific energy points including touch on the fingers, toes, and parts of the upper arm, upper calf and lower leg.

"There is a need for additional research to develop evidence-based interventions that have a positive impact on the quality of life for all of these individuals without adding to their burden," says Bradley, who regards this as a quality of life issue as much as anything else. "From what I have seen in my office and the results shown in the study, I believe that Jin Shin Jyutsu has great promise in this area."

Source: Medical News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap